Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives $38.67 Consensus PT from Analysts

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) has earned a consensus recommendation of “Hold” from the five analysts that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $38.6667.

A number of research analysts recently commented on PHAR shares. Oppenheimer reiterated an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Weiss Ratings restated a “sell (d)” rating on shares of Pharming Group in a report on Friday, August 7th. Zacks Research lowered Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Finally, Canaccord Genuity Group lifted their target price on Pharming Group from $37.00 to $38.00 and gave the company a “buy” rating in a report on Monday, August 3rd.

Pharming Group Stock Performance

Shares of Pharming Group stock opened at $11.21 on Monday. The stock’s 50 day simple moving average is $12.07 and its 200-day simple moving average is $13.84. The stock has a market cap of $793.44 million, a P/E ratio of 93.42 and a beta of 0.01. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.01 and a quick ratio of 2.31. Pharming Group has a 1-year low of $9.62 and a 1-year high of $21.34.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. Analysts predict that Pharming Group will post 0.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

A number of large investors have recently modified their holdings of the company. NewEdge Advisors LLC increased its holdings in Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after buying an additional 28,615 shares during the last quarter. Millennium Management LLC acquired a new position in Pharming Group during the fourth quarter worth approximately $360,000. SmartHarvest Portfolios LLC acquired a new position in shares of Pharming Group in the 4th quarter valued at $224,000. Finally, EverSource Wealth Advisors LLC acquired a new position in Pharming Group in the second quarter valued at $32,000. 0.03% of the stock is owned by hedge funds and other institutional investors.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.

Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.